Smarticles are fully charge reversible liposomes for the in vivo drug delivery of nucleotides like siRNA or antisense to targeted cells.
Steffen Panzner, founder and chief scientific officer of Novosom, said: “The broad grant of this family of patents in key jurisdictions reflects the originality of our approach in the field of oligonucleotide delivery. Both offices have accepted wide claim language which secures comprehensive protection of the amphoteric liposome concept irrespective of any chemical representation for Novosom and its licensees.”